Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study

The optimal strategy for difficult-to-treat (D2T) rheumatoid arthritis (RA) has not been identified, and the ultrasound characteristics of D2T RA have not been reported. We investigated the clinical characteristics and factors contributing to the outcome in D2T RA in a multicentre RA ultrasound obse...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of rheumatology 2024-03, Vol.53 (2), p.123-129
Main Authors: Michitsuji, T, Fukui, S, Morimoto, S, Endo, Y, Nishino, A, Nishihata, S, Tsuji, Y, Shimizu, T, Umeda, M, Sumiyoshi, R, Koga, T, Iwamoto, N, Origuchi, T, Ueki, Y, Yoshitama, T, Eiraku, N, Matsuoka, N, Okada, A, Fujikawa, K, Ohtsubo, H, Takaoka, H, Hamada, H, Tsuru, T, Nawata, M, Arinobu, Y, Hidaka, T, Tada, Y, Kawakami, A, Kawashiri, S-Y
Format: Article
Language:English
Subjects:
Abatacept - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - diagnostic imaging
Arthritis, Rheumatoid - drug therapy
Cohort Studies
Humans
Ultrasonography
Ultrasonography, Doppler
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The optimal strategy for difficult-to-treat (D2T) rheumatoid arthritis (RA) has not been identified, and the ultrasound characteristics of D2T RA have not been reported. We investigated the clinical characteristics and factors contributing to the outcome in D2T RA in a multicentre RA ultrasound observational cohort. We reviewed 307 Japanese patients diagnosed with RA who underwent treatment with biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). We compared the differences in patient characteristics between the D2T RA and non-D2T RA groups. We examined the factors contributing to a good response [defined as b/tsDMARD continuation and Clinical Disease Activity Index (CDAI) ≤ 10 at 12 months] in the D2T RA patient group. Forty-three patients (14%) were categorized as D2T RA and the remaining 264 (86%) as non-D2T RA at baseline. The grey-scale (GS) score, disease duration, and CDAI at the initiation of treatment were significantly higher in the D2T RA group than in the non-D2T RA group. In contrast, the power Doppler (PD) score was not significantly different between the two groups. Of the 43 D2T RA patients, 20 achieved a good response. The introduction of CTLA4-Ig (n = 5) was significantly associated with a good response in analysis based on inverse probability weighting with propensity score. GS and PD scores at baseline were not significantly associated with therapeutic response at 12 months in D2T RA patients. Patients with D2T RA had high clinical and ultrasound activity and poor responses to treatment with b/tsDMARDs. CTLA4-Ig was associated with a good response at 12 months in D2T RA patients.
ISSN:0300-9742
1502-7732
DOI:10.1080/03009742.2023.2277542